Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Fenebrutinib?
Fenebrutinib is a small molecule commercialized by Roche, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS). According...
Fenebrutinib by Genentech USA for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
Fenebrutinib is under clinical development by Genentech USA and currently in Phase III for Primary Progressive Multiple Sclerosis (PPMS). According...
Fenebrutinib by Genentech USA for Follicular Lymphoma: Likelihood of Approval
Fenebrutinib is under clinical development by Genentech USA and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
Fenebrutinib by Genentech USA for Mantle Cell Lymphoma: Likelihood of Approval
Fenebrutinib is under clinical development by Genentech USA and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
Fenebrutinib by Genentech USA for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Fenebrutinib is under clinical development by Genentech USA and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
Fenebrutinib by Genentech USA for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Fenebrutinib is under clinical development by Genentech USA and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
Fenebrutinib by Genentech USA for Non-Hodgkin Lymphoma: Likelihood of Approval
Fenebrutinib is under clinical development by Genentech USA and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...